A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

This study is testing a specialized cell therapy called MB-CART19.1 — a treatment where immune cells are engineered to find and destroy lymphoma cells — in people with central nervous system (CNS) lymphoma, a type of cancer that grows in the brain or spinal cord. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with CNS lymphoma (specifically diffuse large B-cell subtype) that has come back or stopped responding to treatment - You have received at least one prior treatment targeting the brain/CNS (methotrexate-based therapy) - Imaging or spinal fluid tests show active disease **You may NOT be eligible if...** - Your cancer has not returned or is still responding to current treatment - You have not received any prior CNS-directed therapy - You have serious infections, organ failure, or other health conditions that would make this treatment too risky - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.